> Studies on actual infections rates seem to be almost completely absent.
Numerous studies have been presented to ACIP over the last few years covering asymptomatic infections, symptomatic infections, and hospitalizations. From the 2021 meeting covering Pfizer-BioNTech, there were 5, [1] 17 [2], and 13 [3] of these studies, respectively. There are similar sets for Moderna [4]. From what I've seen of the ACIP meetings, those are the results they focused on the most.
I don't have much knowledge of medical research but I don't see how this could possibly be "completely absent". Would love to hear more about what's missing from these and the dozens of other studies which have been done since.
https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-bivale...
Which seems to be entirely lacking in efficacy data. MMWR just has immunogenicity and speculation, too:
https://www.cdc.gov/mmwr/volumes/71/wr/mm7145a2.htm